121 completed, 30 unknown, 21 recruiting, 19 terminated. 207 Phase 3, 56 Phase 2.
Follow Control: new trials by email Literature Review of Control trials Research Report on Control
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Tenecteplase or Alteplase- depending upon availability at each treating centre, Control - Stroke, Acute Ischemic, Endovascular Thrombectomy | Phase 3 | Recruiting | University of Calgary | 1500 | 2026-08-11 | 2026-10-21 |
| A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia. APC101, Control - PHN - Post-Herpetic Neuritis | Phase 2 / Phase 3 | Not yet recruiting | Andros Pharmaceuticals Co., Ltd. | 333 | 2026-08-01 | 2026-05-20 |
| A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation TSC-101, Control - AML, MDS | Phase 3 | Active not recruiting | TScan Therapeutics, Inc. | 310 | 2026-06-18 | 2026-10-05 |
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children VLA1553, Control - Chikungunya Virus Infection | Phase 3 | Withdrawn | Valneva Austria GmbH | 2026-02-06 | 2025-12-31 | |
| Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease Extra 600mg of Rifampicin, Placebo - Pulmonary TB | Phase 3 | Not yet recruiting | Hamilton Health Sciences Corporation | 1000 | 2026-02-01 | 2025-08-12 |
| Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma 10% urea lotion plus 1% cannabidiol, Control - Mediciine, Systemic Sclerosis (SSc) | Phase 3 | Recruiting | Khon Kaen University | 36 | 2025-11-05 | 2025-11-24 |
| Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control - Respiratory Distress Syndrome, Pre-term Infants | Phase 3 | Recruiting | Aerogen Pharma Limited | 520 | 2025-09-24 | 2026-10-13 |
| Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY) 0.05% atropine eye drops, 0.025% atropine eye drops, placebo eye drops - Myopia | Phase 3 | Recruiting | Ocus Innovation Ireland Limited | 234 | 2025-09-01 | 2026-02-11 |
| A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients CAR T cells, Control - Gastric Adenocarcinoma | Phase 3 | Recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 150 | 2025-08-06 | 2025-10-23 |
| Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia Methoxyflurane - Penthrox, Control, Percocet Pill - Benign Prostate Hypertrophy(BPH) | Phase 3 | Not yet recruiting | University of Manitoba | 48 | 2025-08-01 | 2025-06-12 |
| The SCOPE Trial: Sleep, Cognition, and Pain Bundle vs. ERAS-cardiac for Postoperative Delirium Sleep Hygiene, Brain Game, and IV Acetaminophen Intervention, Control - Delirium, Postoperative, Delirium in Old Age | Phase 3 | Recruiting | Beth Israel Deaconess Medical Center | 406 | 2025-06-06 | 2026-04-15 |
| Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar PvSeroTAT, Control - Malaria Vivax, Malaria Falciparum | Phase 3 | Recruiting | London School of Hygiene and Tropical Medicine | 19200 | 2025-05-12 | 2026-09-18 |
| Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery Colchicine, Placebo - Cardiovascular Diseases, Cardiovascular Complication | Phase 3 | Recruiting | Cantonal Hospital of St. Gallen | 880 | 2025-04-20 | 2025-04-24 |
| Probiotic Supplements in Osteoarthritis Probiotic Formula, Control - Osteoarthritis, Knee | Phase 3 | Completed | Beni-Suef University | 146 | 2025-02-15 | 2026-07-24 |
| Adjuvant Cerebroprotection Using Normobaric Hyperoxia in Pre-hospital Patients with Suspected Stroke NBO, Control - Stroke Acute | Phase 3 | Not yet recruiting | Capital Medical University | 1000 | 2025-02-01 | 2025-01-30 |
| Normobaric Oxygen in AIS Transferred for EVT NBO, Control - Ischemic Stroke | Phase 3 | Recruiting | Capital Medical University | 1500 | 2024-12-13 | 2025-12-11 |
| Efficacy of INM004 in Children With STEC-HUS INM004, Placebo - Hemolytic-Uremic Syndrome | Phase 3 | Recruiting | Inmunova S.A. | 220 | 2024-10-05 | 2026-01-15 |
| The Use of Melatonin for Delirium Prevention in Medically Hospitalized Patients Intervention 1, Intervention 2, Control - Delirium | Phase 2 / Phase 3 | Recruiting | Sultan Qaboos University | 240 | 2024-09-30 | 2025-01-14 |
| A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality JUVÉDERM® VOLITE™, Control - Skin Quality Deficit | Phase 2 / Phase 3 | Completed | AbbVie | 135 | 2024-07-18 | 2026-02-18 |
Showing 20 of 207. Sign in to see all of them.
COVID-19 (5) · Neoplasms (5) · Obesity (5) · Premature Birth (5) · Respiratory Distress Syndrome (5) · Stroke (5) · Burns (4) · Ischemic Stroke (4) · Myocardial Infarction (4) · Breast Neoplasms (3) · Cardiovascular Diseases (3) · Coronavirus Infections (3) · Diabetic Foot (3) · HIV Infections (3) · Infertility (3)
Medline Industries (4) · Royan Institute (4) · The University of Texas Medical Branch, Galveston (4) · AbbVie (3) · Dompé Farmaceutici S.p.A (3) · Shanghai University of Traditional Chinese Medicine (3) · Assistance Publique - Hôpitaux de Paris (2) · Assiut University (2) · Bio-Medical Research, Ltd. (2) · Capital Medical University (2) · Children's Hospital of Philadelphia (2) · Colgate Palmolive (2) · Fresenius Kabi (2) · GIE Medical (2) · GlaxoSmithKline (2)
United States (73) · Canada (20) · China (20) · France (16) · Spain (16) · Brazil (12) · Germany (12) · Italy (12) · United Kingdom (11) · Egypt (9) · Australia (8) · Belgium (7) · Poland (6) · South Korea (6) · Iran (5)
David N Herndon, MD (4) · Hamid Gourabi, PhD (3) · Daniel Romer, PhD (2) · Hossein Baharvand, PhD (2) · Jerilynn Radcliffe, PhD (2) · Julio J Ochoa, Ph.D. (2) · Ling Xu, MD & PhD (2) · Nikolai Sopko, MD, PhD (2) · A Bhansali (1) · Abbot R. Laptook, MD (1) · Abhik Das, PhD (1) · Aisha K Yousafzai, PhD (1) · Alberto Zangrillo, MD PhD (1)
PMID 38837240, PMID 39356039, PMID 11914403, PMID 12165594, PMID 12807523, PMID 15951714, PMID 16221780, PMID 17079582, PMID 17213237, PMID 17679633, PMID 17955107, PMID 18515527, PMID 18534246, PMID 18720323, PMID 18762517, PMID 18829776, PMID 19020525, PMID 19252411, PMID 19270260, PMID 19364999, PMID 19618698, PMID 19734776, PMID 19944358, PMID 19948631, PMID 20126343, PMID 20350189, PMID 20424252, PMID 20495811, PMID 20881067, PMID 20921569, PMID 20925928, PMID 21118924, PMID 21377930, PMID 21410418, PMID 21479243, PMID 21566232, PMID 21674390, PMID 21674393, PMID 21675354, PMID 21806579, PMID 21809337, PMID 22103808, PMID 22116817, PMID 22186969, PMID 22221277, PMID 22299027, PMID 22352784, PMID 22463890, PMID 22563751, PMID 22606232
2009 (2), 2014 (2), 2023 (1), M01RR000030 (1), M01RR000039 (1), M01RR000044 (1), M01RR000070 (1), M01RR000080 (1), M01RR000633 (1), M01RR000750 (1), M01RR006022 (1), M01RR007122 (1), M01RR008084 (1), M01RR016587 (1), P50GM060338 (1)